Auranofin is a gold salt classified by the World Health Organization as an antirheumatic agent. It has the brand name Ridaura. Use
Auranofin is used to treat rheumatoid arthritis. It improves arthritis symptoms including painful or tender and swollen joints and morning stiffness. Auranofin is a safer treatment compared to the more common injectable gold thiolates (gold sodium thiomalate and gold thioglucose), but meta-analysis of 66 clinical trials concluded that it is somewhat less effective.The drug was approved for the treatment of rheumatoid arthritis in 1985. No longer a first-line treatment for rheumatoid arthritis, due to its adverse effects, "most of which are associated with long-term use for chronic disease. The most common adverse effects are gastrointestinal complaints such as loose stools, abdominal cramping and watery diarrhea, which can develop in the early months of treatment. The development of loose stools occurs in 40 % of patients, while watery diarrhea is reported in just 2–5 % of patients, and in most cases these symptoms were alleviated by reducing or splitting the dose". Research
HIV infection
Auranofin is under investigation as a means of reducing the viral reservoir of HIV that lies latent in the bodys T-cells despite treatment with antiretroviral therapy. The drug was shown to reduce the amount of latent virus in monkey trials. A human study testing auranofin and other investigational treatments is ongoing in Brazil. Preliminary results show that auranofin contributed to a decrease in the viral reservoir.
Granulomatous prostatitis is an uncommon disease of the prostate, an exocrine gland of the male reproductive system. It is a form of prostatitis (prostate inflammation), resulting from infection (bacterial, viral, or fungal), BCG vaccine, malacoplakia or systemic granulomatous diseases which involve the prostate. Pathogenesis
Prostatic secretions escape into the stroma and elicit an inflammatory response. Histopathology
Noticeable destruction of Acini, surrounded by epitheloid cells, giant cells, lymphocytes, plasma cells and dense fibrosis. References


== External links ==